N-Methyl-D-Aspartate Receptors (NMDA Receptors)

A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity.

Also Known As:

Networked: 10352 relevant articles (428 outcomes, 1290 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dalmau, Josep: 77 articles (01/2022 - 01/2007)
2.	Vincent, Angela: 55 articles (05/2021 - 04/2009)
3.	Hashimoto, Kenji: 39 articles (01/2022 - 02/2002)
4.	Prüss, Harald: 38 articles (10/2022 - 02/2012)
5.	Coyle, Joseph T: 35 articles (01/2021 - 01/2002)
6.	Traynelis, Stephen F: 30 articles (04/2022 - 09/2005)
7.	Dale, Russell C: 29 articles (01/2022 - 11/2009)
8.	Pan, Hui-Lin: 29 articles (01/2022 - 08/2009)
9.	Felipo, Vicente: 28 articles (07/2022 - 04/2002)
10.	Tanaka, Keiko: 27 articles (12/2021 - 01/2010)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 04/01/2014 - "Are NMDA receptor antagonists beneficial in the treatment of schizophrenia?" 05/01/2009 - "In summary, these data demonstrate that PCP-induced deficits in NMDA receptor function, neurotoxicity and subsequent behavioral deficits may be prevented by D1R activation in the cortex and further, it is suggested that D1R activation may be beneficial in treating schizophrenia." 12/01/2020 - "Using a Bayesian prediction error minimization model, we describe how congenital visual loss may be protective against the development of the kind of computational deficits postulated to underlie schizophrenia, by increasing the precision (and consequent stability) of higher-level (including supramodal) priors, focusing on visual loss-induced changes in NMDA receptor structure and function as a possible mechanistic substrate. " 01/01/2009 - "Through the study of these models, our improved understanding of how the brain adapts to persistent NMDA receptor hypofunction may eventually suggest new therapeutic strategies for schizophrenia." 01/01/2013 - "Our work has implications for the preclinical use of NMDA receptor antagonists in the prediction of potential therapeutic efficacy in the search for novel treatments for schizophrenia. "
2.	Seizures (Absence Seizure) 03/25/2013 - "However, in field conditions, treatment may be delayed and with the exception of NMDA receptor antagonists, currently no drug provides protection (against lethality, seizures, SRBD and neurological consequences) when seizures are left unabated for one hour or more. " 04/01/1990 - "We report experiments performed to determine if NMDA receptor antagonists are effective in stopping seizures in the late stages of SE. " 01/01/2008 - "Our previous data proved the efficacy of the NMDA-receptor antagonists on the symptoms, survival and neuronal activation in the 4-aminopyridine- (4-AP) induced seizures. " 10/09/1999 - "These findings suggest that pregnancy affords some protection against seizures induced by an activation of NMDA receptors in the brain." 06/01/2019 - "This study aims to investigate the neurobiological consequences of undernourishment and recurrent seizures exposure early in life, investigating Long-Term Potentiation (LTP) induction and gene expression of NMDA receptor subunits in the hippocampus during adulthood (P60). "
3.	Ischemia 08/01/1991 - "We conclude that systemically administered noncompetitive NMDA receptor antagonists do not provide a marked protection against neuronal damage after a transient period of severe forebrain ischemia." 12/01/1992 - "Recent therapeutic studies have demonstrated the efficacy of non-NMDA receptor antagonists in experimental studies of global ischemia." 06/01/2008 - "NMDA receptor blocker ameliorates ischemia-reperfusion-induced renal dysfunction in rat kidneys." 06/01/2005 - "Increased extracellular K+ concentration reduces the efficacy of N-methyl-D-aspartate receptor antagonists to block spreading depression-like depolarizations and spreading ischemia." 01/01/2022 - "Together, this study shows that alterations in NMDA receptor function following preconditioning ischemia are associated with neuroprotection in rapid ischemic tolerance."
4.	Pain (Aches) 02/01/2000 - "Our results suggest that intrathecal administration of MgSO(4) may be therapeutically beneficial for patients with tonic pain involving the spinal NMDA receptors." 08/01/2004 - "These results confirm low efficacy of acute administration of NMDA receptor antagonists in the models of established pain states. " 08/01/2004 - "Thus, studies on the prevention and management of chronic pain should focus on preemptive or long-term administration of NMDA receptor antagonists." 10/01/2008 - "NR2B-selective inhibitors show lower side-effects in preclinical pain models than non-selective NMDA receptor (NMDAR) antagonists, but it is unclear whether the improved safety of NR2B-selective inhibitors is due to their subtype selectivity or to a unique mode of inhibition of the receptor. " 01/01/2019 - "NMDA receptor antagonists and pain relief: A meta-analysis of experimental trials."
5.	Brain Ischemia (Cerebral Ischemia) 07/01/1993 - "Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP40116 in a rat model of focal cerebral ischemia: an in vivo magnetic resonance imaging study." 01/01/1993 - "In the clinical management of cerebral ischemia not only the intrinsic neuronal degenerative process, but also the deteriorating extracellular milieu, needs to be treated, and the latter may not be improved by NMDA receptor blockade.(ABSTRACT TRUNCATED AT 400 WORDS)" 01/01/2018 - "Although clinical trials for NMDA receptor blockers have failed, the role of GluN2A subunit in cerebral ischemia has been extensively evaluated in recent years. " 08/01/2016 - "Recent studies have shown that GSRd can protect against cerebral ischemia through several pathways, one of which is mediated by the N-methyl-D-aspartate receptor (NMDAR). " 03/01/2009 - "As a whole, the study demonstrates that preconditioning attenuation of pro-death JNK3 in the hippocampus CA1 following global cerebral ischemia is mediated by NMDA receptor-induced crosstalk between ERK1/2 and JNK3. "

Related Drugs and Biologics

1.	N-Methylaspartate (NMDA)
2.	Ketamine
3.	Dizocilpine Maleate (Dizocilpine)
4.	Memantine (Namenda)
5.	Glycine (Aminoacetic Acid)
6.	Glutamic Acid (Glutamate)
7.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
8.	Antipsychotic Agents (Antipsychotics)
9.	Serine (L-Serine)
10.	Antidepressive Agents (Antidepressants)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Analgesia
4.	Injections
5.	Drug Therapy (Chemotherapy)